fda compounding semaglutide warning november 2025 The Risks of Compounded Products FDA Warning Letter Breakdown: Sterility

The brand matters less than the specification

Semaglutide and tirzepatide have been under shortage pressure since 2023 as demand for the branded formulations (Ozempic, Wegovy, Mounjaro, Zepbound) outpaced manufacturing capacity

503A pharmacies compound medications for specific individual patients based on a valid prescription from a licensed prescriber

It is essential to monitor your progress at every visit to ensure that the medication is working appropriately

Clinical trials have shown that retatrutide can lower HbA1c (a key marker of blood sugar control) by more than 2%, a remarkable improvement compared to many existing treatments